ARA-290 10 mg — Research Protocol

Quickstart Highlights

Ara-290 (cibinetide) is an 11–amino acid non-erythropoietic peptide derived from erythropoietin’s helix-B domain^[1]. It selectively activates the innate repair receptor (IRR), an EPOR/CD131 heterodimer, to promote anti-inflammatory and tissue-protective effects without stimulating red blood cell production^[2]. Clinical trials have demonstrated benefits for diabetic neuropathy and sarcoidosis-related small-fiber neuropathy^[3][4].

Storage Instructions

Proper storage preserves peptide integrity and potency.

• Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2 years; freeze at −20 °C (−4 °F) for extended storage up to 3 years^[6].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days and do not freeze the liquid solution^[7].
• Allow vials to reach room temperature before opening to minimize condensation; protect from light.
• Discard if discoloration, cloudiness, or particulate matter is observed.

How It Works

Ara-290 (cibinetide) binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (βc subunit), which is distinct from the classical erythropoietin receptor^[1][2]. This selective binding triggers anti-apoptotic and anti-inflammatory signaling cascades that protect tissues and promote repair without stimulating erythropoiesis^[9]. Preclinical research demonstrates that Ara-290 can reprogram a pro-inflammatory, tissue-damaging environment into one favoring healing and regeneration^[10]. Additionally, analgesic effects have been observed through immunomodulation and direct inhibition of TRPV1 ion channels activated by capsaicin^[11].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Neuroprotection: Clinical trials in diabetic neuropathy showed improvements in HbA1c, lipid profiles, and neuropathic pain scores with 4 mg daily dosing^[3].
• Nerve regeneration: In sarcoidosis-associated small-fiber neuropathy, treatment led to significant increases in corneal nerve fiber density (objective nerve regrowth) and improved symptoms compared to placebo^[4].
• Tissue protection: Anti-inflammatory and anti-apoptotic effects observed across multiple organ systems in preclinical models^[9].
• No erythropoietic effects: Unlike full EPO, Ara-290 does not stimulate red blood cell production, avoiding related side effects^[2].
• Tolerability: Well tolerated in clinical studies; occasional mild injection-site reactions (redness, transient discomfort) may occur with subcutaneous administration.

References

• IUPHAR/BPS Guide to PharmacologyCibinetide (ARA-290) ligand profile: structure, receptor binding, and pharmacology
• Molecular Medicine (2008)Brines & Cerami: Discovery and development of the innate repair receptor and its non-erythropoietic ligands
• Molecular Medicine (2014)Brines M. et al.: ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
• Molecular Medicine (2013)Dahan A. et al.: ARA 290 improves symptoms in sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
• ClinicalTrials.gov (NCT02039687)Phase 2 study of ARA 290 on corneal nerve fiber density in sarcoidosis (1 mg vs 4 mg vs 8 mg daily SC for 28 days)
• NCBI BookshelfStability and storage considerations for lyophilized peptide formulations
• USP General ChaptersPharmaceutical compounding with bacteriostatic water: stability and beyond-use dating
• Cleveland ClinicSubcutaneous injections: where and how to administer at home
• Pain Reports (2017)Davis T. et al.: Targeting the innate repair receptor to treat neuropathy (review of ARA-290 mechanisms)
• Investigative Ophthalmology & Visual Science (2016)Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy
• Peptides Journal (2016)Zhang W. et al.: ARA 290 relieves pathophysiological pain by targeting TRPV1 channel
• Johns Hopkins Arthritis CenterHow to give a subcutaneous injection: patient guide
• CDCVaccine administration: subcutaneous route (angle, site, and technique guidance)
• PMC Subcutaneous Drug Delivery ReviewPharmacologic considerations of the subcutaneous injection route